Molecular Epidemiology Of Escherichia Coli Strains In Urinary Tract Infections: Virulence Factors And Antibiotic Resistance Patterns
Abstract
Urinary tract infections (UTIs) are a significant clinical challenge, with Escherichia coli (E. coli) being the leading causative pathogen in both community- and hospital-acquired infections. This study investigates the virulence factors and antibiotic resistance patterns of E. coli strains isolated from symptomatic and asymptomatic UTI patients. A total of 230 E. coli strains were isolated from 2483 urine samples collected over 18 months. The study identified a high prevalence of virulence factors such as hemolysin, siderophores, and cell surface hydrophobicity, particularly in symptomatic patients. Multidrug-resistant (MDR) E. coli strains, including those producing extended-spectrum β-lactamase (ESBL) enzymes, were also identified, complicating treatment strategies. The presence of the CTX-M gene in several strains further underscores the need for careful antibiotic stewardship and continuous monitoring of resistance patterns.
References
2. Poirel, L., Heussler, H., Nordmann, P. (2012). Genetic features of blaCTX-M genes. Antimicrobial Agents and Chemotherapy, 56(1), 283-287.
3. Woodford, N., Carattoli, A., Karisik, E., et al. (2009). Complete nucleotide sequence of a blaCTX-M-15-encoding IncFII plasmid from Escherichia coli K1 and investigation of the phylogeny of IncFII plasmids carrying blaCTX-M-15. Antimicrobial Agents and Chemotherapy, 53(11), 4565-4570.
4. Johnson, J. R., & Russo, T. A. (2005). Molecular epidemiology of extraintestinal pathogenic (uropathogenic) Escherichia coli. International Journal of Medical Microbiology, 295(6-7), 383-404.
5. Foxman, B. (2010). The epidemiology of urinary tract infection. Nature Reviews Urology, 7(12), 653-660.
6. Falagas, M. E., Kastoris, A. C., Kapaskelis, A., & Karageorgopoulos, D. E. (2010). Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Escherichia coli infections: A systematic review. The Lancet Infectious Diseases, 10(1), 43-50.
7. Pitout, J. D. D., & Laupland, K. B. (2008). Extended-spectrum beta-lactamase-producing Enterobacteriaceae: An emerging public-health concern. The Lancet Infectious Diseases, 8(3), 159-166.
8. Rodriguez-Bano, J., Navarro, M. D., Romero, L., et al. (2008). Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. Journal of Clinical Microbiology, 46(8), 2794-2799.
9. Ensor, V. M., Shahid, M., Evans, J. T., & Hawkey, P. M. (2006). CTX-M enzymes are the most common extended-spectrum beta-lactamases in Escherichia coli isolates from patients in the United Kingdom. Journal of Antimicrobial Chemotherapy, 58(1), 160-164.
10. Hooton, T. M. (2012). Uncomplicated urinary tract infection. New England Journal of Medicine, 366(11), 1028-1037.